Samsung Biologics Eyes $5bn CDO Backlog as K-Pharma Bets on Biosimilar Supercycle

DART Decoded Editorial Desk

Independent analysis of Korean DART filings & KRX market data · June 10, 2026

Korean equities surged on Wednesday — KOSPI +1.63% to 7,606.3, KOSDAQ an even more aggressive +2.99% to 938.67 — and the bio & pharma complex rode the rally hard. The sector has moved from a niche KOSDAQ story to a structural KOSPI heavyweight, underpinned by three converging forces: a contract development and manufacturing (CDMO) capacity arms race, an accelerating global biosimilar substitution wave, and a pipeline of novel central-nervous-system drugs edging toward US approval. With USD/KRW at 1,524.48, the export revenue translation tailwind is meaningful for every company that invoices in dollars.

The Capacity War Behind the Backlog Number

Samsung Biologics (KOSPI:207940) has emerged as the single most important proxy for global biologics outsourcing demand. The Incheon-based CDMO now operates four plants with a combined capacity approaching 604,000 litres — the largest single-site biologics manufacturing footprint on earth — and Plant 5 is scheduled to come online in late 2026, adding another 180,000 litres. Management's guidance of a cumulative contract backlog above $5 billion signals that capacity is being absorbed almost as fast as it is built.

The strategic pivot worth watching is the push into cell & gene therapy (CGT) manufacturing. Samsung Biologics has quietly signed several CGT pilot agreements with mid-sized US biotechs that cannot afford in-house viral-vector capacity. While CGT currently represents a rounding error in revenue, the margin profile — typically two to three times that of monoclonal antibody fill-finish — makes it a long-term margin catalyst that analysts are only beginning to model.

Samsung Biologics' Plant 5 will bring total licensed capacity to roughly 784,000 litres by end-2026 — more than double the next-largest CDMO competitor outside of Lonza.

Celltrion's Transatlantic Biosimilar Momentum

Celltrion (KOSPI:068270) has spent the past two years transforming from a pure manufacturer into a fully integrated biopharma with its own commercial salesforce in the US and Europe. That bet is paying off. Its adalimumab biosimilar — a direct competitor to AbbVie's Humira, still one of the world's top-selling drugs — has gained formulary access at several major US pharmacy benefit managers following the 2023 interchangeability designation from the FDA.

The more immediate catalyst is the subcutaneous formulation of its infliximab biosimilar (a follow-on to Remicade), where Celltrion holds a first-mover advantage in several EU markets. European payer pressure on reference biologics remains intense, and biosimilar penetration rates in major indications like rheumatoid arthritis and inflammatory bowel disease are still below 60% in many southern European markets — representing a significant volume runway.

Equally important is the company's pipeline beyond the first generation of TNF-alpha inhibitors. A Phase 3 programme for a CT-P59 variant (targeting a respiratory indication) and early-stage work on an ophthalmic biosimilar are beginning to attract attention from US institutional investors who previously dismissed Celltrion as a single-product story.

SK Biopharmaceuticals: The CNS Outlier in the Group

SK Biopharmaceuticals (KOSPI:326030) occupies a different lane entirely. Its cenobamate (branded as Xcopri in the US, marketed by SK Life Science) has now been on the US market for several years and is demonstrating one of the strongest seizure-freedom rates in refractory focal epilepsy seen in modern clinical trials. Monthly prescription volumes have climbed steadily, and the drug is entering the part of the adoption curve where neurologist word-of-mouth drives non-linear volume growth.

Two upcoming data readouts matter for the stock. First, expanded-use data in paediatric populations could significantly widen the addressable patient pool. Second, the European commercial rollout — handled through a partnership structure — is at an earlier stage of penetration than the US, providing a second growth vector that is not yet fully priced by the consensus. With the won weak against the dollar, Xcopri's USD-denominated US royalty stream translates into a meaningful earnings uplift.

Company Comparison: Scale, Revenue Mix and Pipeline Depth

Company	KRX Ticker	Primary Model	Key Near-Term Catalyst	FX Sensitivity
Samsung Biologics	KOSPI:207940	CDMO / contract mfg	Plant 5 licence & CGT pilot revenues	High (USD contracts)
Celltrion	KOSPI:068270	Integrated biopharma	US adalimumab share gains; SC infliximab EU roll-out	High (EUR/USD sales)
SK Biopharmaceuticals	KOSPI:326030	CNS innovator	Cenobamate paediatric data; EU volume ramp	High (USD royalties)
Yuhan	KOSPI:000100	Domestic pharma / licensing	Lazertinib (Rybrevant) global sales milestone payments	Moderate (milestone USD)
Green Cross	KOSPI:006280	Plasma / vaccines	WHO prequalification renewal; plasma fractionation expansion	Low-moderate

Yuhan's Lazertinib Milestone Machine

Yuhan (KOSPI:000100) represents a different kind of Korean pharma story: a domestic generics-and-OTC stalwart that licensed a genuinely novel oncology asset — the EGFR inhibitor lazertinib — to Johnson & Johnson, which commercialises the combination regimen under the brand Rybrevant in the US and Europe. As that combination therapy continues to accumulate prescriptions in first-line non-small cell lung cancer, Yuhan is entitled to a tiered royalty stream that functions as a high-margin annuity. Analysts expect cumulative milestones and royalties to exceed $300 million over the next three years, a sum that dwarfs the company's traditional domestic earnings base.

The Yuhan case is instructive for understanding Korean pharma's maturation: the country has moved from generic manufacturing to out-licensing novel molecules, and at least half a dozen smaller Korean biotechs are now attempting to replicate the Yuhan-J&J template.

Green Cross: The Quiet Infrastructure Play

Green Cross (KOSPI:006280) rarely makes international headlines, but it is one of Asia's most important plasma fractionation platforms. Its immunoglobulin and albumin products supply hospital systems across Korea, Southeast Asia and parts of the Middle East. The company is expanding its Ochang plant to handle higher plasma input volumes, positioning it to benefit from a structural global shortage of fractionated plasma products — a shortage driven by demographic ageing and increasing clinical use of IVIG therapy in neurological conditions.

Forward Catalysts to Watch

Q2 2026 earnings season (July): Samsung Biologics' order-book update will be the bellwether for CDMO sector sentiment. Any commentary on Plant 5 utilisation ahead of schedule would be a positive signal.
FDA advisory committee calendar: SK Biopharmaceuticals' paediatric cenobamate supplemental NDA is expected to receive an advisory committee date in late 2026; an early scheduling announcement would be a catalyst.
EU biosimilar tender results (Q3): Several southern European national health systems are conducting annual tender rounds for infliximab and adalimumab; Celltrion's win rate will determine H2 European volume guidance.
Lazertinib global sales disclosure: J&J's quarterly earnings (next due mid-July 2026) will include Rybrevant combination revenue, from which Yuhan's royalty accruals can be inferred.
Green Cross WHO prequalification: A successful renewal of its plasma-derived product prequalification would open UN procurement channels, materially expanding addressable volume.

The Won's Double-Edged Role

USD/KRW at 1,524.48 is near multi-year highs, and for a sector that earns substantially in dollars and euros, the translation effect is unambiguously positive in the near term. Samsung Biologics invoices CDMO contracts in USD; Celltrion's US commercial revenues are dollar-denominated; SK Biopharmaceuticals' Xcopri royalties arrive in dollars. A sustained weak-won environment inflates reported Korean won revenue and operating profit without any underlying volume change — a tailwind that consensus earnings estimates may not fully reflect if they were built on more moderate FX assumptions earlier in the year.

The risk, of course, is that a weaker won also raises the cost of dollar-denominated raw materials — particularly cell culture media and single-use bioreactor consumables — where Korean CDMOs remain dependent on US and European suppliers. Samsung Biologics has been working to localise parts of its consumable supply chain, but full localisation is still several years away.

Disclaimer: Sector analysis is for informational purposes only. Not investment advice.

How this analysis was prepared

Source data: DART (Korea's Electronic Disclosure System), KRX market data, and global market feeds via yfinance. Korean filings were translated to English in full; numerical data is presented as filed. No third-party investment recommendations are referenced or implied.

Search This Blog

DART Decoded